DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Anoma Ranaweera, Medical Writer, Auckland, New Zealand. DermNet Chief Editor in Chief: Adjunct A/Prof Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand. First published December 2013; updated April 2020. Copy edited by Gus Mitchell/Maria McGivern.
Omalizumab (trade name Xolair™) is a humanised monoclonal antibody that binds to circulating immunoglobulin E (IgE) and reduces the release of inflammatory mediators from mast cells and basophils. It is given by subcutaneous injection once every 4 weeks.
Omalizumab was licensed in New Zealand as an add-on therapy for patients with severe, persistent allergic asthma and for patients 12 years of age or older with severe chronic spontaneous urticaria that remain symptomatic despite H1-antihistamine treatment. It is funded by PHARMAC on Special Authority application under certain circumstances.
Results of three several phase III trials ASTERIA I, ASTERIA II, and GLACIAL trials support the efficacy of omalizumab in chronic spontaneous urticaria.
This global, multicenter, randomised, double-blind, placebo-controlled study was funded by Genentech and Novartis Pharma; ClinicalTrials.gov number, NCT01292473. It has shown that omalizumab reduces symptoms in chronic urticaria.
|Omalizumab 300 mg||-9.8||p < 0.001|
|Omalizumab 150 mg||-8.1||p = 0.001|
|Omalizumab 75 mg||-5.9||p = 0.46|
The X‐ACT study aimed to examine the effect of omalizumab treatment on quality of life (QoL) in chronic spontaneous urticaria (CSU) patients with angioedema refractory to high doses of H1‐antihistamines .
In this phase III double-blind randomised study patients were randomised 1:1 to receive omalizumab 300 mg SC or placebo every 4 weeks for 28 weeks. 68 patients (omalizumab, n = 35; placebo, n = 33) completed the 28‐week treatment period. All were chronic spontaneous urticaria patients (18–75 years) with ≥ 4 angioedema episodes during the 6 months before inclusion.
Angioedema‐related quality of life (QoL), skin‐related QoL impairment, and psychological well‐being were assessed. At baseline, the mean (SD) total Angioedema QoL (AE‐QoL; 56.2 [18.7] and 59.9 [19.2]) and Dermatology Life Quality Index (DLQI; 14.6 [5.7] and 16.6 [7.3]) score were high in the omalizumab and placebo groups, respectively.
Following omalizumab treatment initiation, the mean angio-oedema activity scores (AAS7); consisting of an opening question (Have you had a swelling episode in the last 24 hours?), followed by the five specific AAS questions to determine the severity and impact of the angioedema episode, decreased rapidly with significant differences observed as early as Week 4 through to Week 28.
The mean (SD) AAS7 scores increased to placebo levels (omalizumab, 10.2 [19.6]; placebo, 9.8 [12.0]) after discontinuation of omalizumab at Week 36.The most severely affected subdomains of the AE‐QoL were fears/shame, fatigue/mood, and functioning.
The most severely affected subdomains of the DLQI score included daily activities and leisure. General psychological and well-being improved with omalizumab treatment. In the omalizumab group, the mean (SD) WHO‐5 score (The World Health Organisation -5 Well-Being Index) was 10.0 (5.5) at baseline and increased above the depression threshold to 18.6 (5.1) by the end of the treatment period. The corresponding results in the placebo group were 7.7 (5.3) at baseline and 11.5 (5.8) at Week 28 (least square mean difference between groups at Week 28, p < 0.001).
This study attempted to determine the effectiveness of omalizumab in treating severe atopic dermatitis in children.
So far, there is no evidence that omalizumab is disease-modifying. When patients stopped the study drug, their symptoms recurred. At the end of 16 weeks off treatment, symptoms of urticaria were similar to patients treated with placebo. When omalizumab was restarted in patients that had previously responded, the omalizumab was again effective.
IgE autoantibodies are also detected in a large number of patients with atopic dermatitis and bullous pemphigoid. In individual case reports, omalizumab treatment has been reported to be effective in some patients with these conditions. It has also been reported effective in chronic recurrent angioedema.
If you are not based in New Zealand, we suggest you refer to your national drug approval agency for further information about medicines (eg, the Australian Therapeutic Goods Administration and the US Food and Drug Administration) or a national or state-approved formulary (eg, the New Zealand Formulary and New Zealand Formulary for Children and the British National Formulary and British National Formulary for Children).
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.